vs
Side-by-side financial comparison of REPLIGEN CORP (RGEN) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.
UL Solutions Inc. is the larger business by last-quarter revenue ($340.0M vs $194.3M, roughly 1.8× REPLIGEN CORP). On growth, REPLIGEN CORP posted the faster year-over-year revenue change (14.8% vs -12.4%). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (12.3% CAGR vs -31.8%).
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...
The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.
RGEN vs ULS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $194.3M | $340.0M |
| Net Profit | $8.3M | — |
| Gross Margin | 55.7% | — |
| Operating Margin | 8.2% | 24.4% |
| Net Margin | 4.3% | — |
| Revenue YoY | 14.8% | -12.4% |
| Net Profit YoY | 42.9% | — |
| EPS (diluted) | $0.15 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $194.3M | $340.0M | ||
| Q4 25 | $197.9M | $789.0M | ||
| Q3 25 | $188.8M | $783.0M | ||
| Q2 25 | $182.4M | $776.0M | ||
| Q1 25 | $169.2M | $705.0M | ||
| Q4 24 | $174.1M | $739.0M | ||
| Q3 24 | $154.9M | $731.0M | ||
| Q2 24 | $154.1M | $730.0M |
| Q1 26 | $8.3M | — | ||
| Q4 25 | $13.3M | $67.0M | ||
| Q3 25 | $14.9M | $100.0M | ||
| Q2 25 | $14.9M | $91.0M | ||
| Q1 25 | $5.8M | $67.0M | ||
| Q4 24 | $-30.3M | $81.0M | ||
| Q3 24 | $-654.0K | $88.0M | ||
| Q2 24 | $3.3M | $101.0M |
| Q1 26 | 55.7% | — | ||
| Q4 25 | 52.5% | 49.7% | ||
| Q3 25 | 53.2% | 50.3% | ||
| Q2 25 | 50.0% | 49.4% | ||
| Q1 25 | 53.6% | 48.4% | ||
| Q4 24 | 26.1% | 47.4% | ||
| Q3 24 | 50.0% | 49.0% | ||
| Q2 24 | 49.8% | 50.1% |
| Q1 26 | 8.2% | 24.4% | ||
| Q4 25 | 9.0% | 15.0% | ||
| Q3 25 | 8.9% | 19.9% | ||
| Q2 25 | 7.6% | 17.9% | ||
| Q1 25 | 3.9% | 15.5% | ||
| Q4 24 | -17.7% | 15.6% | ||
| Q3 24 | -5.1% | 17.8% | ||
| Q2 24 | 1.0% | 17.3% |
| Q1 26 | 4.3% | — | ||
| Q4 25 | 6.7% | 8.5% | ||
| Q3 25 | 7.9% | 12.8% | ||
| Q2 25 | 8.2% | 11.7% | ||
| Q1 25 | 3.4% | 9.5% | ||
| Q4 24 | -17.4% | 11.0% | ||
| Q3 24 | -0.4% | 12.0% | ||
| Q2 24 | 2.2% | 13.8% |
| Q1 26 | $0.15 | — | ||
| Q4 25 | $0.24 | $0.33 | ||
| Q3 25 | $0.26 | $0.49 | ||
| Q2 25 | $0.26 | $0.45 | ||
| Q1 25 | $0.10 | $0.33 | ||
| Q4 24 | $-0.55 | $0.40 | ||
| Q3 24 | $-0.01 | $0.44 | ||
| Q2 24 | $0.06 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $582.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $2.9B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $582.6M | — | ||
| Q4 25 | $767.6M | $295.0M | ||
| Q3 25 | $748.7M | $255.0M | ||
| Q2 25 | $708.9M | $272.0M | ||
| Q1 25 | $697.2M | $267.0M | ||
| Q4 24 | $757.4M | $298.0M | ||
| Q3 24 | $784.0M | $327.0M | ||
| Q2 24 | $809.1M | $295.0M |
| Q1 26 | — | — | ||
| Q4 25 | $542.2M | $491.0M | ||
| Q3 25 | $537.9M | $544.0M | ||
| Q2 25 | — | $608.0M | ||
| Q1 25 | — | $653.0M | ||
| Q4 24 | $525.6M | $742.0M | ||
| Q3 24 | — | $797.0M | ||
| Q2 24 | — | $810.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $1.3B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $2.0B | $970.0M | ||
| Q4 24 | $2.0B | $904.0M | ||
| Q3 24 | $2.0B | $872.0M | ||
| Q2 24 | $2.0B | $769.0M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $2.9B | ||
| Q3 25 | $2.9B | $2.9B | ||
| Q2 25 | $2.9B | $2.9B | ||
| Q1 25 | $2.9B | $2.9B | ||
| Q4 24 | $2.8B | $2.8B | ||
| Q3 24 | $2.8B | $2.9B | ||
| Q2 24 | $2.9B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.26× | 0.39× | ||
| Q3 25 | 0.26× | 0.46× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | 0.27× | 0.82× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGEN
| Product | $194.2M | 100% |
| Royalty and other revenue | $44.0K | 0% |
ULS
Segment breakdown not available.
